 | |
| open access article - requires password (chart: ovarian cancer - 7th column from the left) | http://jnci.oxfordjournals.org/content/104/1/13/F1.expansion.html |
Tuesday, February 21, 2012
StatBite National Costs for Cancer Care in 2010 in Billions of Dollars by Cancer Site
Nurses Wanted: Largest Women's Health Study Seeks 100,000 Nurses
Nurses Wanted: Largest Women's Health Study Seeks 100,000 Nurses: Nurses' Health Study recruits "next generation"
Why Does Patient Activation Matter? An Examination of the Relationships Between Patient Activation and Health-Related Outcomes
This Commonwealth Fund–supported study sought to investigate the extent to which patient activation, as assessed by the Patient Activation Measure (PAM), is related to health and utilization outcomes among a large group of insured patients.
open access: The patient, the illness, the doctor, the decision: negotiating a ‘new way’ through person-centered medicine - International Journal of Person Centered Medicine
"As we write, nowhere within modern medicine is the need for greater understanding more acutely necessary than in its philosophy of the patient as a person......
Full Text: PDF
abstract: Inflammation in cancer cachexia: To resolve or not to resolve (is that the question?)
Inflammation in cancer cachexia: To resolve or not to resolve (is that the question?)
Abstract
Background & aims
Cachexia is associated with poor prognosis and shortened survival in cancer patients. Growing evidence points out to the importance of chronic systemic inflammation in the aetiology of this syndrome. In the recent past, chronic inflammation was considered to result from overexpression and release of pro-inflammatory factors. However, this conception is now the focus of debate, since the importance of a crescent number of pro-resolving agents in the dissolution of inflammation is now recognised – leading to the hypothesis that chronic inflammation occurs rather due to failure in the resolution process. We intend to put forward the possibility that this may also be occurring in cancer cachexia.
Methods
Recent reviews on inflammation and cachexia, and on the factors involved in the resolution of inflammation are discussed.
Results
The available information suggests that indeed, inflammation resolution failure may be present in cachexia and therefore we speculate on possible mechanisms.
Conclusions
We emphasise the importance of studying resolution-related mechanisms in cancer cachexia and propose the opening of a new venue for cachexia treatment.
Current Issue : Clinical Obstetrics and Gynecology March 2012 - Volume 55 - Issue 1
Blogger's Note: this is a paid subscription journal
abstract: First-line Chemotherapy in Epithelial Ovarian Cancer : Clinical Obstetrics and Gynecology
Abstract
"Advanced-stage epithelial ovarian cancer remains a highly lethal malignancy, despite effective cytoreductive surgery and primary chemotherapy. Phase III studies have evaluated multidrug combinations, dose-dense weekly scheduling, intraperitoneal delivery, neoadjuvant chemotherapy, maintenance therapy, and targeting of angiogenesis. Incremental gains in median progression-free or overall survival have been achieved, but without an impact on overall mortality. Data support intraperitoneal cisplatin, dose-dense weekly paclitaxel, or neoadjuvant chemotherapy with interval cytoreduction in appropriate patients. Encouraging data have emerged using antiangiogenic agents, but with questions regarding optimal timing and patient selection. The use of 3-drug combinations or maintenance chemotherapy is not supported."
abstract: Strengthening the Case for Stool DNA Tests as First-Line Colorectal Cancer Screening: Are We There Yet? (of interest to Lynch Syndrome patients/genetically predisposed)
Blogger's Note: while limited information is available through the abstract it does touch on patient issues regarding screening, this will be of interest to Lynch Syndrome/genetically predisposed patients for which guidelines recommend frequent screening (standard colonoscopy vs virtual colonoscopy)
Abstract
"The incidence of and mortality from colorectal cancer (CRC) have decreased in countries that have established population-based screening programs. In the United States, incidence rates decreased 4% annually from 2003–2007, and mortality decreased by 3.3% per year.1 During this same time period, rates of screening in the U.S. increased from 50% to 65%,2 with colonoscopy-based programs being the predominant strategy in many regions of the country. However, despite increased public education and improved access to colonoscopy in the U.S., 35% of patients still fail to undergo CRC screening,2 likely because of this procedure's invasiveness, need for bowel preparation, as well as sedation and missed days of work. Furthermore, the effectiveness of colonoscopy, which has long been considered the gold standard in CRC screening, has recently come into question, with population-based studies demonstrating disappointing outcomes with right-sided lesions and serrated adenomas."
The Challenge of Choosing Appropriate End Points in Single-Arm Phase II Studies of Rare Diseases [JCO Editorials] - opens in pdf file
".......In this era, with more agents to test in smaller, more specific
cohorts of patients, we can no longer afford minimally active drugs to
pass phase II studies and to enter phase III trials. In addition to
potentially exposing patients to unnecessary adverse effects from an
inactive compound, these studies may inhibit the evaluation of other
regimens in that particular group of patients. It is hoped that novel
means to measure antitumor activity at an early time point in phase II
studies may accelerate drug development. For example, a decline in
numbers of circulating tumor cells just 3 to 6 weeks after initiation of
treatment is strongly associated with overall survival in several epithelial
malignancies,11 but whether such new tools will offer significant
advantages compared with response rate and stabilization of disease
remains to be determined. A high response rate and durable disease
stabilization are probably pivotal determinants for improved quality
of life and/or prolonged overall survival and, ultimately, that is what
we want from novel regimens.
Furthermore, it is time to be more ambitious. Before starting
clinical trials, we should intensify our efforts to reveal the mechanisms
of action of the agents that we want to study, which will allow more
precise identification of the target population. We should determine
whether these preclinical targets are truly modulated, and in early
clinical trials we should aim for clinically meaningful response rates
and particularly long progression-free periods, determined by international consensus per tumor entity. Eventually, this will result in a
higher success rate of phase III studies, smaller number of patients
needed in these studies to show clinically relevant differences, and
most importantly, more rapid availability of active new drugs for
our patients."
Call for Changes in Clinical Trial Reporting of Older Patients With Cancer [Correspondence] opens in pdf file
"In studies in which older patients make up a significant proportion
(>15%) of the study population, an analysis of the possible
interaction between outcome, toxicity, and age should be provided in
detail according to specific patient characteristics (comorbidity, function,
and so on). Toxicity should include a reporting of grade 2 toxicities,
when appropriate, given that grade 2 toxicity can be significant in
a patient age 75 years."
"In sum, clinical trials currently fail to address the issues involved
in treating an aging patient with cancer. Designers of clinical cancer
trials must begin to incorporate statistical analyses related to aging, so
that clinicians can optimize their treatment of the older patient
with cancer."
Retraction: An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer
Retraction
“An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer” by Holly K. Dressman, Andrew Berchuck, Gina Chan, Jun Zhai, Andrea Bild, Robyn Sayer, Janiel Cragun, Jennifer Clarke, Regina S. Whitaker, LiHua Li, Jonathan Gray, Jeffrey Marks, Geoffrey S. Ginsburg, Anil Potti, Mike West, Joseph R. Nevins, and Johnathan M. Lancaster (J Clin Oncol 25:517–525, 2007)
The majority of the authors wish to retract this article because they have identified several instances of misalignment of genomic and clinical outcome data. Although a reanalysis of correctly aligned data still demonstrated a capacity to predict patient response to platinum-based therapy, the accuracy of these predictions has been reduced from 77.8% to 72.2%, and as a result, the original conclusions have been compromised. The authors deeply regret the impact of this action on the work of other investigators.
The following authors agreed with this retraction decision: Andrew Berchuck, Gina Chan, Janiel Cragun, Holly K. Dressman, Geoffrey S. Ginsburg, Jonathan Gray, Johnathan M. Lancaster, Jeffrey Marks, Joseph R. Nevins, Anil Potti, Mike West, and Regina S. Whitaker.
The following authors disagreed with this retraction decision: Andrea Bild, Jennifer Clarke, LiHua Li, and Jun Zhai.
The following author could not be reached for comment: Robyn Sayer.
This article was retracted on January 27, 2012.
Monday, February 20, 2012
New source found for cancer drug Doxil, in short supply - USATODAY.com - Lipodox
"Patients with ovarian cancer and other deadly
tumors will regain access to an important chemotherapy drug, Food and
Drug Administration officials told USA TODAY in an exclusive interview
Monday. The
drug, Doxil, has been in short supply since last June. There are no
generic versions of the drug, which is also used to treat multiple
myeloma and AIDS-related Kaposi's sarcoma.
The
agency says it will announce today that it has worked out a deal to
temporarily import a replacement drug, called Lipodox, from an Indian
company, says the FDA's Sandra Kweder. The FDA has previously inspected the company, Sun Pharma Global, which exports the drug to other companies....."
open access: TB Peritonitis Mistaken for Ovarian Carcinomatosis Based on an Elevated CA-125
Discussion
"In this patient, the delay in the diagnosis of tuberculous pertitonitis resulted in what may have been unnecessary radical resection of her reproductive organs. This was unfortunate as peritoneal TB is felt to be medically manageable with the standard four-drug antituberculous regimen for 6 months with the expectation that symptoms will start improving after the first week of therapy [2, 6]. If surgery is indicated, delayed surgery following medical management significantly reduces complications [3]........This case outlines the unfortunate consequences of the misdiagnosis of what probably was an antibiotic responsive illness, resulting in an unnecessarily aggressive surgical procedure."
also:
Two Cases of Ascites. - The Hong Kong Society for Infectious ...
www.hksid.org/pdf/twocasesofascites.pdf -Guest post: Time to bring human genome sequencing into the clinic « Genomes Unzipped
Guest post: Time to bring human genome sequencing into the clinic
I have just published in Nature a commentary discussing the need to bring exome and genome sequencing into the clinical arena, so that these data are generated with the same rigorous clinical standards as for any other clinical test. This way, we can then easily return at least medically actionable results to research participants. In this day and age of consumer and patient empowerment, I can also see eventually returning all data, including the raw data, to any interested participants, as this can then promote crowd-sourcing for data analysis, with research participants controlling and promoting the relative privacy of and analysis of their own data......
ELC : Investigator Insights: VEGF and VEGFR Inhibitors in Gynecologic Malignancies
Blogger's Note: requires registration
CME expires 2013
Investigator Insights: VEGF and VEGFR Inhibitors in Gynecologic Malignancies
Preclinical and clinical investigations provide a strong rationale for the use of angiogenesis inhibitors in ovarian primary peritoneal/fallopian tube cancer, and a large variety of angiogenesis inhibitors are in late stages of development. Drs. Thomas Herzog and Robert Burger discuss VEGF and VEGFR inhibitors including emerging data from clinical trails, management of toxicities and the future direction of this field.
abstract: Preventable Exposures Associated With Human Cancers
Abstract:
Information on the causes of cancer at specific sites is important to cancer control planners, cancer researchers, cancer patients, and the general public. The International Agency for Research on Cancer (IARC) Monograph series, which has classified human carcinogens for more than 40 years, recently completed a review to provide up-to-date information on the cancer sites associated with more than 100 carcinogenic agents. Based on IARC’s review, we listed the cancer sites associated with each agent and then rearranged this information to list the known and suspected causes of cancer at each site. We also summarized the rationale for classifications that were based on mechanistic data. This information, based on the forthcoming IARC Monographs Volume 100, offers insights into the current state-of-the-science of carcinogen identification. Use of mechanistic data to identify carcinogens is increasing, and epidemiological research is identifying additional carcinogens and cancer sites or confirming carcinogenic potential under conditions of lower exposure. Nevertheless, some common human cancers still have few (or no) identified causal agents.
Information on the causes of cancer at specific sites is important to cancer control planners, cancer researchers, cancer patients, and the general public. The International Agency for Research on Cancer (IARC) Monograph series, which has classified human carcinogens for more than 40 years, recently completed a review to provide up-to-date information on the cancer sites associated with more than 100 carcinogenic agents. Based on IARC’s review, we listed the cancer sites associated with each agent and then rearranged this information to list the known and suspected causes of cancer at each site. We also summarized the rationale for classifications that were based on mechanistic data. This information, based on the forthcoming IARC Monographs Volume 100, offers insights into the current state-of-the-science of carcinogen identification. Use of mechanistic data to identify carcinogens is increasing, and epidemiological research is identifying additional carcinogens and cancer sites or confirming carcinogenic potential under conditions of lower exposure. Nevertheless, some common human cancers still have few (or no) identified causal agents.
abstract: Effect of Ginger on Acute and Delayed Chemotherapy-Induced Nausea and Vomiting: A Pilot, Randomized, Open-Label Clinical Trial - in breast cancer
Effect of Ginger on Acute and Delayed Chemotherapy-Induced Nausea and Vomiting: A Pilot, Randomized, Open-Label Clinical Trial:
Background.
Nausea and vomiting are among the most prevalent and disturbing side effects of chemotherapy. Therefore, there is a need for additional antiemetic agents that could effectively reduce chemotherapy-induced nausea and vomiting (CINV), whether alone or in combination with current standard therapies. Since clinical data on the effectiveness of ginger in patients with advanced breast cancer is lacking, the present study aimed to evaluate the effects of ginger against both acute and delayed forms of CINV in a population with advanced breast cancer as the main malignancy.
Methods. In this pilot, randomized, open-label clinical trial, 100 women (mean age = 51.83 ± 9.18 years) with advanced breast cancer who were initially assigned to standard chemotherapy protocol with docetaxel, epirubicin, and cyclophosphamide (the TEC regimen) were randomized to receive ginger (1.5 g/d in 3 divided doses every 8 hours) plus standard antiemetic regimen (granisetron plus dexamethasone; the ginger group) or standard antiemetic regimen alone (control group). The duration of treatment with ginger was specified to 4 days from the initiation of chemotherapy. Prevalence, score, and severity of nausea, vomiting, and retching were assessed using a simplified form of Rhodes index in the first 6 hours, between 6 to 24 hours, and days 2, 3, and 4 postchemotherapy.
Results. A significantly lower prevalence of nausea was observed in the ginger group during 6 to 24 hours postchemotherapy. Despite this effect, no other significant additional benefit from ginger (1.5 g/d) was observed against prevalence or severity of nausea, vomiting, and retching in any of the assessed periods.
Conclusion. Addition of ginger (1.5 g/d) to standard antiemetic therapy (granisetron plus dexamethasone) in patients with advanced breast cancer effectively reduces the prevalence of nausea 6 to 24 hours postchemotherapy. However, there is no other additional advantage for ginger in reducing prevalence or severity of acute or delayed CINV.
abstract: Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies
Abstract
Circulating, cell-free microRNAs (miRNAs) hold great promise as a new class of cancer biomarkers due to their surprisingly high stability in plasma, association with disease states, and ease of sensitive measurement. Yet little is known about the origin of circulating miRNAs in either healthy or sick people or what factors influence levels of circulating miRNA biomarkers. Of 79 solid tumor circulating miRNA biomarkers reported in the literature, we found that 58% (46 of 79) are highly expressed in one or more blood cell type. Plasma levels of miRNA biomarkers expressed by myeloid (e.g., miR-223, miR-197, miR-574-3p, and let-7a) and lymphoid (e.g., miR-150) blood cells tightly correlated with corresponding white blood cell counts. Plasma miRNA biomarkers expressed by red blood cells (e.g., miR-486-5p, miR-451, miR-92a, and miR-16) could not be correlated to red cell counts due to limited variation in hematocrit in the cohort studied but were significantly increased in hemolyzed specimens (20- to 30-fold plasma increase; P < 0.0000001).
Finally, in a patient undergoing autologous hematopoietic cell transplantation, plasma levels of myeloid- and lymphoid-expressed miRNAs (miR-223 and miR-150, respectively) tracked closely with changes in corresponding blood counts. We present evidence that blood cells are a major contributor to circulating miRNA and that perturbations in blood cell counts and hemolysis can alter plasma miRNA biomarker levels by up to 50-fold.
Given that a majority of reported circulating miRNA cancer biomarkers are highly expressed in blood cells, we suggest caution in interpretation of such results as they may reflect a blood cell-based phenomenon rather than a cancer-specific origin. Cancer Prev Res; 5(3); 1–6. ©2011 AACR.
blogger: Women of Teal: Link Up: 10 Things You Probably Didn't Know About Me
Monday, February 20, 2012
(blog) Women of Teal:
Link Up: 10 Things You Probably Didn't Know About Me
Traitorous Immune Cells Promote Sudden Ovarian Cancer Progression | Wistar
Wiki:
Dendritic cells (DCs) are immune cells forming part of the mammalian immune system. Their main function is to process antigen material and present it on the surface to other cells of the immune system. That is, dendritic cells function as antigen-presenting cells. They act as messengers between the innate and adaptive immunity.
~~~~~~~~~~~~
"Aggressive ovarian tumors begin as malignant cells kept in check by the immune system until, suddenly and unpredictably, they explode into metastatic cancer. New findings from José R. Conejo-Garcia's lab demonstrate that ovarian tumors don’t necessarily break “free” of the immune system, rather dendritic cells of the immune system seem to actively support the tumor’s escape. The researchers show that it might be possible to restore the immune system by targeting a patient’s own dendritic cells....."
National Guideline Clearinghouse | ACR practice guideline for communication of diagnostic imaging findings.
Blogger's Note: selected section of interest:
~~~~~~~~~~~~~~~~
Self-Referred and Third Party Referred Patients
Most patients having imaging procedures are referred by physicians or other health care professionals. Some patients, however, are self-referred, such as for mammography, or are referred by a third party, such as an insurer or employer.
- Self-Referred Patients Interpreting physicians should recognize that performing imaging studies on self-referred patients establishes a doctor-patient relationship that includes responsibility for communicating the results of imaging studies directly to the patient and arranging for appropriate follow-up.
- Third-Party Referred Patients It is not unusual for patients to be referred for imaging studies by insurance companies, employers, federal benefits programs, and in some instances lawyers. In such cases the reports of the studies are frequently communicated through the requesting entity to a clinician or directly to the third-party-designated clinician. The results of the examinations are then communicated to the patient either directly by the third party or by its designated clinician. Regardless of the source of the referral, the interpreting physician has an ethical responsibility to ensure communication of unexpected or serious findings to the patient. Therefore, in certain situations the interpreting physician may feel it is appropriate to communicate the findings directly to the patient.
abstract: ‘My wig has been my journey's companion’: perceived effects of an aesthetic care programme for Italian women suffering from chemotherapy-induced alopecia
‘My wig has been my journey's companion’: perceived effects of an aesthetic care programme for Italian women suffering from chemotherapy-induced alopecia:
This study explored the perceived effects of an aesthetic care/wig programme for Italian women suffering from chemotherapy-induced alopecia. Despite advances in the treatment of many side effects of chemotherapy, alopecia remains difficult to resolve. Literature suggests that patients' reactions to alopecia and camouflaging strategies depend on their gender, individual characteristics, social context, and culture. A qualitative study was designed involving 20 patients from Sicily (Italy), who participated in an aesthetic care programme. Data were collected through semi-structured interviews, and an Interpretative Phenomenological Analysis was conducted on transcriptions. Our findings showed that, even if expected, alopecia is experienced as a traumatic event that challenges a woman's femininity, as reported by many other enquiries. Diverging from other studies, the wig is perceived as very helpful, since it camouflages baldness and reduces the ‘sick aspect’ related to alopecia. Patients consider their wig to be a ‘friend’, and it appears that through the aesthetic care programme they received support they otherwise would not have sought. We conclude that aesthetic care/wig programmes can help women affected by alopecia to cope with cancer ‘stigma’, especially in those rural contexts where psychosocial programmes are not frequently embraced by patients due to environmental and cultural barriers.
2011 National Guideline Clearinghouse | Antiemetics (nausea): American Society of Clinical Oncology clinical practice guideline update.
also note:
FDA Warning/Regulatory Alert
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.
- September 15, 2011 – Zofran (ondansetron)
: The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients of an ongoing safety review and labeling changes for the anti-nausea drug Zofran (ondansetron, ondansetron hydrochloride and generics). Ondansetron may increase the risk of developing prolongation of the QT interval of the electrocardiogram, which can lead to an abnormal and potentially fatal heart rhythm, including Torsade de Pointes.
open access: JNCI - Commentary Improved Outcomes in the Malnourished Patient: We’re Not There Yet
".......By outlining the limitations, the authors provide direction for future researchers. A key point made by the authors is that despite the statistical significance of some aspects of QOL, it is unclear how meaningful these changes are to the patient. The challenge that researchers face is explaining how improved emotional well-being resulted from taking an oral nutritional supplement and/or receiving dietary counseling. Was the improvement from the nutritional counseling, the supplement, the combination, or the extra attention to and clinical involvement with the patient....."
"....Nutritional supplements may indeed improve outcomes for some patients experiencing malnutrition but not cachexia. Dietary counseling may be beneficial for patients at high risk for malnutrition and their caregivers. However, the research conducted to date is fraught with limitations; hence, it is challenging for clinicians to apply these results to everyday practice."
Sunday, February 19, 2012
recruiting: The Molecular Predisposition to (Lynch Syndrome) (HNPCC) - ClinicalTrials.gov - see Blogger's Notes on this trial
Blogger's Note:
this trial does not include a spectrum of Lynch Syndrome-associated cancers such as; ovarian, brain, pancreatic - all high mortality rate cancers except research indicates that those with genetic syndromes (in general) have improved survival rates; there may be a connection as to what and what has not been included (cancer sites) as this is a 15 yr observational study; however, if interested in participating, the contact information is below; it would be interesting to understand the (exclusion by default) inclusion rationale and in particular relating to those of the rarer cancer sites in Lynch Syndrome
~~~~~~~~~~~~~~~~~~~~~~~~
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
This study is currently recruiting participants.
Verified December 2011 by M.D. Anderson Cancer Center
First Received on October 4, 2011. Last Updated on December 20, 2011 History of Changes
Please refer to this study by its ClinicalTrials.gov identifier: NCT01447199
Please refer to this study by its ClinicalTrials.gov identifier: NCT01447199
| Contact: Patrick Lynch, MD, JD | 713-794-5073 |
Purpose
The goal of this study is to understand factors which may influence risk for colorectal and other cancers in families. These factors include genetic variability, in combination with diet and lifestyle. In order to achieve these goals, the investigators need to contact as many eligible participants as possible.
This study proposes to identify genetic risk factors that predispose to colorectal cancer (CRC). The focus of this study will be to understand the role of the mismatch repair genes responsible for Hereditary Non-polyposis Colorectal Cancer (HNPCC), i.e., hMSH2, hMLH1 and other mismatch repair genes and modifier genes in combination with diet and lifestyle in familial and de novo colon cancer cases. By examining the status of the mismatch repair genes in both normal and neoplastic tissues among mismatch repair gene mutation carriers, family members not carrying the mutation and non-HNPCC families, it will be possible to determine the role of the mismatch repair genes in the development of colon cancer within HNPCC families.
| Condition | Intervention |
|---|---|
| Bladder Cancer Colorectal Cancer Endometrial Cancer Kidney Cancer Skin Cancer Uterus Cancer | Behavioral: Health and Diet Questionnaire |
not yet recruiting: A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 - Full Text View - ClinicalTrials.gov
A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901
This study is not yet open for participant recruitment.
Verified February 2012 by Duke University
First Received on January 24, 2012. Last Updated on February 1, 2012 History of Changes
| Sponsor: | Duke University |
|---|---|
| Collaborator: | Department of Defense |
| Information provided by (Responsible Party): | Duke University |
| ClinicalTrials.gov Identifier: | NCT01526473 |
Purpose
HER2 is a protein that is over expressed in 20-30% of breast cancers. It is also found associated with lung, gastric, ovarian, and pancreatic cancers. Although there are existing therapies that can target HER2, most patients will eventually experience progression of their disease even though their cancer continues to express HER2. Therefore, new approaches are needed for treating tumors that express HER2.
This clinical trial will use an investigational cancer vaccine called HER2 VRP or AVX901. The vaccine is based on a virus called Venezuelan equine encephalitis but it has been changed so it cannot cause active infection. Instead, the virus has been changed so it tells the immune system to attack cancer cells which make HER2.
The objectives of the study are to evaluate the safety of immunization with HER2 VRP in patients with advanced or metastatic malignancies that express HER2, and to test whether immunization will causes a strong immune system attack against the cancer.
| Condition | Intervention | Phase |
|---|---|---|
| HER2+ Cancer | Biological: AVX901 | Phase I |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | A Phase I Study To Evaluate The Antitumor Activity And Safety Of DUKE-002-VRP(HUHER2-ECD+TM), An Alphaviral Vector Encoding The HER2 Extracellular Domain And Transmembrane Region, In Patient With Locally Advanced Or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Cancers Including Breast Cancer |
Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer - Full Text View - ClinicalTrials.gov
This study is currently recruiting participants.
Verified January 2012 by Memorial Sloan-Kettering Cancer Center
First Received on November 10, 2011. Last Updated on January 30, 2012 History of Changes
| Sponsor: | Memorial Sloan-Kettering Cancer Center |
|---|---|
| Information provided by (Responsible Party): | Memorial Sloan-Kettering Cancer Center ( Memorial Sloan-Kettering Cancer Center ) |
| ClinicalTrials.gov Identifier: | NCT01471483 |
Purpose
Older woman with ovarian cancer have a worse prognosis compared to younger patients. However, the reason is not known. Currently, the standard of care is to evaluate younger and older patients with cancer the same way. However, older patients with cancer often have more complicated issues to manage. For example, older patients often have other medical problems, take more medications, and be dependent on others for help and transportation. Too often, the medical team is unaware of these issues which can effect the patients care.
The purpose of this study is to apply a set of questions designed specifically for patients with cancer who are older than 65 years of age. These questions are called a geriatric assessment.
The investigators want to better understand which older patients with ovarian cancer will be able to tolerate the chemotherapy and surgery and why. This study will also see if a telephone call from a nurse who specializes in caring for older patients will improve patient care. This study will determine how feasible it is to perform geriatric assessments and telephone calls in patients with ovarian cancer.
| Condition | Intervention |
|---|---|
| Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer | Behavioral: geriatric assessment and telephone call from nurse Other: geriatric assessment and no call from nurse |
| Study Type: | Observational |
Subscribe to:
Posts
(
Atom
)
